Bronchitis Treatment Market By Type Of Drug Class (Antitussives/ Expectorants, Bronchodilators, Beta-Adrenergic Agonist, Systemic Corticosteroids, Inhaled Corticosteroids, Phosphodiesterase-4 Inhibitors, Analgesics, Antibiotics) - Growth, Future Prospects, Competitive Analysis, 2018 - 2026

Industry Outlook

Bronchitis treatment market accounted for a market value of US$ 3,345.8 Mn in 2017 and projected to grow at a CAGR of 4.9% during the forecast period from 2018 to 2026. Bronchitis treatment market is growing gradually throughout the forecast period due to strong product pipeline equipped with target-specific drugs, and rising prevalence & awareness related to the treatment & diagnosis of bronchitis. The major cause of bronchitis is frequent cigarette smoking coupled with exposure to air-pollutants.  Thus, overall growth of global bronchitis treatment is significant and expected to maintain its growth throughout the forecast year with the help of upcoming drugs currently present under trials.

Market Synopsis

Get a sample copy for more information

"Continuous research & development in the field of bronchitis treatment expected to bring novel drugs in the market & ultimately assist the overall growth"

During the forecast period from 2018 to 2026, phospodiesterase-4inhibitors identified as the fastest growing segment due to major factors such as Roflumilast are beneficial in chronic bronchitis to decrease exacerbations & relieve dyspnea, and physicians treat chronic bronchitis on priority as its more complex compared to acute bronchitis. Roflumilast also plays key role in improving the lung function and assists recovery of patients. Thus, novel drugs entering in the market will increase the growth of overall bronchitis treatment market, as there is huge market demand for target-specific drugs in the market.

Get a sample copy for more information

"Increasing prevalence & awareness related to the bronchitis in Asia Pacific makes it the fastest growing region throughout the forecast period"

The Asia Pacific will grow significantly throughout the forecast period from 2018 to 2026, the key factors responsible for growth of bronchitis treatment market in this region are rising prevalence of bronchitis due to high level of air-pollution & smoking population, and increasing awareness and accessibility related to bronchitis treatment. There are several awareness campaigns carried out by government and non-government organizations in developing countries of Asia Pacific such as China, India, Indonesia, and Thailand due to which bronchitis treatment market is growing significantly in this region. China & India have highest population suffering with bronchitis that mainly caused due to air-pollution and huge cigarette smoking population. According to World Health Organization (WHO), it has been recorded that in Asia around one third or 2.2 million of the world’s 7 million premature deaths occur due to respiratory disorders caused due to air-pollution each year.

Get a sample copy for more information

Historical & Forecast Period

The bronchitis treatment market analyzed considering current market trends for base year 2017 and based on future trends CAGRs calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

This report provides in-depth analysis related to bronchitis treatment market covering market elucidations and assumptions provided based on in-depth qualitative and quantitative data collected through primary and secondary research. Industry stakeholders have assisted to analyze and study market dynamics such as drivers, opportunities & challenges further concentrated to region-level & country-level. This report also includes comprehensive analysis of global bronchitis treatment market segmented as types of drug class, and geography. The report also gives information related to competitive landscape of the major players present and operate in bronchitis treatment market that covers in-depth data covering company information such as latest business strategies, financial data, & product profiles.

The key manufacturers present in the market reported based on product portfolio, current market updates, financial information, and key strategies. This report also include attractive investment proposition studied with the aid of PESTEL analysis, which based on detailed geographical research. Major companies studied in the overall report are AstraZeneca Plc, DBV Technologies SA, F. Hoffmann-La Roche Ltd., Han Wha Pharma Co. Ltd., and Mucosis BV among others.

Key questions answered in this report

• Which is the trending drug class type in the market preferred for bronchitis treatment & Why?
• What are the current market strategies & policies planned & applied by key companies & competitive landscape of the bronchitis treatment market?
• Which are the important & potential geographical markets (regions and countries) in bronchitis treatment market?
• Which is the largest and fastest growing region globally?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global BT Market Portraiture
2.2. Global BT Market, by Type of Drug Class, 2017 (US$ Mn)
2.3. Global BT Market, by Geography, 2017 Vs 2026 (Value %)

Chapter 3. Global Bronchitis Treatment (BT) Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.2.1. Increasing prevalence and awareness related to bronchitis in developed as well as developing countries
3.2.2. Rising cases of respiratory diseases triggered due to air-pollutants or cigarette smoke
3.3. Challenges
3.3.1. Initial stages of bronchitis are most of the times treated with traditional medicines in Asia Pacific
3.4. Opportunities
3.4.1. Strong pipeline and continuous research and development in the field of BT
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Bronchitis Treatment (BT) Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Antitussives/ Expectorants
4.3. Bronchodilators
4.4. Beta-adrenergic Agonist
4.5. Systemic Corticosteroids
4.6. Inhaled Corticosteroids
4.7. Phosphodiesterase-4 Inhibitors
4.8. Analgesics
4.9. Antibiotics

Chapter 5. Global Bronchitis Treatment (BT) Market: Pipeline Analysis
5.1. Overview
5.2. Phase III [Till 2026] (U$ Mn)
5.2.1. Extracorporeal Photopheresis (ECP)
5.2.2. Cyclosporine
5.3. Phase II (Qualitative Information)
5.3.1. Alteplase
5.3.2. Alvelestat
5.3.3. CKD-497
5.3.4. Treatment-inhaled tPA
5.4. Phase I (Qualitative Information)
5.4.1. HOB-051
5.4.2. Pirfenidone
5.4.3. Aerosolized Infasurf

Chapter 6. Global Bronchitis Treatment (BT) Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. Overview
6.2. North America BT Market Analysis, 2016 – 2026
6.2.1. North America BT Market, by Type of Drug Class, 2016–2026 (US$ Mn)
6.2.2. North America BT Market, by Country, 2016 – 2026 (US$ Mn)
6.2.2.1. U.S.
6.2.2.2. Canada
6.3. Europe BT Market Analysis, 2016 – 2026
6.3.1. Europe BT Market, by Type of Drug Class, 2016–2026 (US$ Mn)
6.3.2. Europe BT Market, by Country, 2016 – 2026 (US$ Mn)
6.3.2.1. U.K.
6.3.2.2. Germany
6.3.2.3. Rest of Europe
6.4. Asia Pacific BT Market Analysis, 2016 – 2026
6.4.1. Asia Pacific BT Market, by Type of Drug Class, 2016–2026 (US$ Mn)
6.4.2. Asia Pacific BT Market, by Country, 2016 – 2026 (US$ Mn)
6.4.2.1. Japan
6.4.2.2. China
6.4.2.3. Rest of APAC
6.5. Latin America BT Market Analysis, 2016 – 2026
6.5.1. Latin America BT Market, by Type of Drug Class, 2016–2026 (US$ Mn)
6.5.2. Latin America BT Market, by Country, 2016 – 2026 (US$ Mn)
6.5.2.1. Brazil
6.5.2.2. Mexico
6.5.2.3. Rest of Latin America
6.6. Middle East & Africa (MEA) BT Market Analysis, 2016 – 2026
6.6.1. Middle East & Africa BT Market, by Type of Drug Class, 2016–2026 (US$ Mn)
6.6.2. MEA BT Market, by Region, 2016 – 2026 (US$ Mn)
6.6.2.1. GCC
6.6.2.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Advanced Inhalation Therapies (AIT) Ltd.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. AstraZeneca Plc
7.3. DBV Technologies SA
7.4. F. Hoffmann-La Roche Ltd.
7.5. Han Wha Pharma Co. Ltd.
7.6. Kyorin Pharmaceutical Co Ltd.
7.7. Merck & Co.
7.8. Mucosis BV
7.9. Orbis Biosciences, Inc.
7.10. Therabron Therapeutics, Inc.
7.11. GlaxoSmithKline plc
7.12. Chong Kun Dang Pharmaceutical
7.13. ONY Biotech Inc.
7.14. Genentech, Inc.
7.15. Daewon Pharm Co. Ltd.

* BT - Bronchitis Treatment

FIG. 1 : Bronchitis Treatment (BT): Market Segmentation
FIG. 2 : Global BT Market Share, by Type of Drug Class, 2017 (US$ Mn)
FIG. 3 : Global BT Market, by Geography, 2017 Vs 2026 (Value %)
FIG. 4 : Attractive Investment Proposition, by Geography, 2017
FIG. 5 : Market Competition Landscape, by Key Players, 2017
FIG. 6 : Global Antitussives/expectorants Market for BT, 2016 – 2026 (US$ Mn)
FIG. 7 : Global Bronchodilators Market for BT, 2016 – 2026 (US$ Mn)
FIG. 8 : Global Beta-adrenergic Agonist Market for BT, 2016 – 2026 (US$ Mn)
FIG. 9 : Global Systemic Corticosteroids for BT Market, 2016 – 2026 (US$ Mn)
FIG. 10 : Global Inhaled Corticosteroids for BT Market, 2016 – 2026 (US$ Mn)
FIG. 11 : Global Phosphodiesterase-4 Inhibitors Market for BT, 2016 – 2026 (US$ Mn)
FIG. 12 : Global Analgesics Market for BT, 2016 – 2026 (US$ Mn)
FIG. 13 : Global Antibiotics Market for BT, 2016 – 2026 (US$ Mn)
FIG. 14 : Global Cyclosporine Market for BT, till 2026 (US$ Mn)
FIG. 15 : Global Extracorporeal Photopheresis (ECP) Market for BT, till 2026 (US$ Mn)
FIG. 16 : U.S. BT Market, 2016 – 2026 (US$ Mn)
FIG. 17 : Canada BT Market, 2016 – 2026 (US$ Mn)
FIG. 18 : U.K. BT Market, 2016 – 2026 (US$ Mn)
FIG. 19 : Germany BT Market, 2016 – 2026 (US$ Mn)
FIG. 20 : Rest Of Europe BT Market, 2016 – 2026 (US$ Mn)
FIG. 21 : Japan BT Market, 2016 – 2026 (US$ Mn)
FIG. 22 : China BT Market, 2016 – 2026 (US$ Mn)
FIG. 23 : Rest Of Asia Pacific BT Market, 2016 – 2026 (US$ Mn)
FIG. 24 : Brazil BT Market, 2016 – 2026 (US$ Mn)
FIG. 25 : Mexico BT Market, 2016 – 2026 (US$ Mn)
FIG. 26 : Rest Of Latin America BT Market, 2016 – 2026 (US$ Mn)
FIG. 27 : GCC BT Market, 2016 – 2026 (US$ Mn)
FIG. 28 : Rest Of Middle East And Africa BT Market, 2016 – 2026 (US$ Mn)

TABLE 1 : Global Bronchitis Treatment (BT) Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 2 : North America BT Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 3 : North America BT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 4 : Europe BT Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 5 : Europe BT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 6 : Asia Pacific BT Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 7 : Asia Pacific BT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 8 : Latin America BT Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 9 : Latin America BT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 10 : Middle East & Africa BT Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 11 : Middle East And Africa BT Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 12 : Advanced Inhalation Therapies (AIT) Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 13 : AstraZeneca Plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 14 : DBV Technologies SA: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 : F. Hoffmann-La Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 : Han Wha Pharma Co. Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 : Kyorin Pharmaceutical Co Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 : Merck & Co.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 : Mucosis BV: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 : Orbis Biosciences, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 : Therabron Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 : GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 : Chong Kun Dang Pharmaceutical: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 : ONY Biotech Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 : Genentech, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 26 : Daewon Pharm Co. Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)